Welcome to our dedicated page for Livongo Health news (Ticker: LVGO), a resource for investors and traders seeking the latest updates and insights on Livongo Health stock.
The Livongo Health, Inc. (LVGO) news page on Stock Titan provides an archive of company-related announcements and media coverage from the period when LVGO traded on Nasdaq. Livongo was a digital health company that described itself as an Applied Health Signals provider, focused on helping people with chronic conditions such as diabetes, hypertension, weight issues, and behavioral health challenges live better and healthier lives.
News items for LVGO include quarterly financial results, updates on key operating metrics, and commentary from company leadership. For example, Livongo’s second and third quarter 2020 releases highlighted year-over-year revenue growth, increases in Livongo for Diabetes membership, client expansion, and the use of its Applied Health Signals platform and AI+AI engine to support consumer-directed virtual care.
Other coverage features strategic partnerships and distribution relationships. These include agreements with organizations such as GuideWell and its subsidiary Florida Blue, as well as partnerships for chronic kidney disease and behavioral health programs. Several articles also discuss Livongo’s pending merger agreement with Teladoc Health, including joint investor conference presentations and references to a joint proxy statement/prospectus filed with the SEC.
Investors and researchers can use this news archive to review how Livongo communicated its strategy, described its chronic condition programs, and positioned its role in virtual care and remote monitoring. Because the available items relate to a specific historical period and mention a proposed merger, this page is best viewed as a record of Livongo’s public narrative and business developments while the LVGO symbol was active.
Define Ventures, a major early-stage health tech venture capital firm, has appointed Carolyn Magill as venture partner. Magill brings 25 years of experience in healthcare, having served as CEO of Aetion and Remedy Partners, and held executive positions at Evolent Health and UnitedHealth Group.
Magill joins existing venture partners Bruce Broussard (former Humana CEO) and Frank Williams (Evolent Health co-founder) to support Define's portfolio companies. The firm, managing $800 million in assets, invests in seed to series B stage companies and has backed notable ventures like Hims & Hers.
Her expertise spans payer, provider, and pharmaceutical sectors, with particular focus on data and AI applications. At Aetion, she led a platform transforming real-world data into regulatory-grade evidence, while at Remedy Partners she oversaw bundled payments software and services.
Mendaera, a Silicon Valley-based healthcare technology company, has secured $73 million in Series B funding led by Threshold Ventures. The company is developing a handheld robotic interventional platform to address healthcare provider shortages and rising costs in mainstream medical procedures.
Mendaera's platform combines robotics, AI, real-time imaging, and virtual connectivity to improve quality and workforce productivity in common procedures like biopsies, organ and vascular access, and pain management interventions. The funding will be used to complete development of the robotic technology, accelerate AI and connectivity capabilities, and begin clinical introduction.
The company aims to enhance patient experience, increase access to high-quality care, reduce overall costs, and improve healthcare provider satisfaction by making advanced technologies more accessible across specialties and sites of service.
Salvo Health has launched a virtual health clinic aimed at addressing chronic gut conditions for over 60 million Americans. The company recently secured $10.5 million in seed funding led by Threshold Ventures, along with Torch Capital and Felicis. Salvo Health offers a comprehensive care model, Whole Self Science, that integrates various health disciplines to provide personalized treatment plans. Their approach includes unlimited access to a dedicated care team, emphasizing root cause treatment over conventional methods. The company plans to expand its services across the U.S.
Livongo Health announced a strong performance in its third quarter 2020, reporting a total revenue of $106.1 million, marking a 126% year-over-year increase. The company has over 442,000 enrolled members for its diabetes program, a rise of 113% year-over-year. Livongo achieved a GAAP gross margin of 75.6% and a non-GAAP net income of $19.2 million, translating to $0.16 per share. The Estimated Value of Agreements (EVA) reached $145.9 million, a 71% increase from the previous year. The company is optimistic about future growth, bolstered by its merger with Teladoc Health.
On October 16, 2020, GuideWell Mutual Holding Corporation announced a strategic partnership with Livongo (Nasdaq: LVGO) to enhance care for members with chronic conditions, specifically diabetes. Florida Blue, a GuideWell subsidiary, will provide access to Livongo's diabetes management platform through the Onlife Health consumer engagement solution. This collaboration aims to offer a comprehensive virtual care experience by integrating Teladoc's virtual care services with Livongo’s data capabilities. Livongo currently serves over 1,300 clients, including major corporations and health plans.
Livongo Health (Nasdaq: LVGO) is set to release its financial results for Q3 FY2020 on October 28, 2020, post-market close. Due to the pending merger with Teladoc Health, no conference call will accompany the announcement. Livongo focuses on empowering individuals with chronic conditions through insights and data-driven health management. Its innovative approach delivers improved clinical outcomes and a better overall experience for members.
On September 8, 2020, Livongo Health (Nasdaq: LVGO) announced upcoming presentations at investor conferences regarding their merger with Teladoc Health. Key events include the Wells Fargo Securities Healthcare Conference on September 10 at 8:00 a.m. ET and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16 at 9:30 a.m. ET. Livongo focuses on empowering individuals with chronic conditions through its AI-driven health solutions, improving health outcomes and experiences. Archives of the webcasts will be available on Livongo's Investor Relations site.
Livongo Health (Nasdaq: LVGO) announced that its executives will present at the KeyBanc Capital Markets Future of Technology Series on August 27, 2020, at 10:00 a.m. ET. The presentation will be available via a live webcast and archived recordings on the company's Investor Relations webpage. Livongo is focused on empowering individuals with chronic conditions, utilizing its AI-driven platform to deliver actionable health insights. The company aims to enhance clinical and financial outcomes through personalized health signals.
Livongo Health, a leader in Applied Health Signals, announced its executives will present at the Canaccord Genuity 40th Annual Growth Conference on August 13, 2020, at 8:30 a.m. ET. The conference will feature discussions on empowering individuals with chronic conditions such as diabetes and hypertension. A live webcast of the presentation will be accessible on the company's Investor Relations website. Livongo uses advanced AI to provide personalized health insights, aiming to improve clinical and financial outcomes for its members.
Livongo Health, Inc. (NASDAQ: LVGO) reported significant growth in its second quarter of 2020, with total revenue reaching $91.9 million, a 125% increase year-over-year. The company enrolled over 410,000 Livongo for Diabetes members, reflecting a 113% rise. The GAAP net loss was $1.6 million, translating to a loss per share of ($0.02). Non-GAAP net income stood at $12.5 million, or $0.11 per diluted share. Livongo's estimated value of agreements grew to $108.7 million, up 46% year-over-year, showcasing its strong market position.